232 related articles for article (PubMed ID: 27245159)
1. Short-term changes of intraocular pressure and ocular perfusion pressure after intravitreal injection of bevacizumab or ranibizumab.
Lee JW; Park H; Choi JH; Lee HJ; Moon SW; Kang JH; Kim YG
BMC Ophthalmol; 2016 May; 16():69. PubMed ID: 27245159
[TBL] [Abstract][Full Text] [Related]
2. The early effects of intravitreal anti vascular endothelial growth factor agents on intraocular pressure and central corneal thickness.
Omay E; Elgin U; Sen E; Yilmazbas P
Int Ophthalmol; 2016 Oct; 36(5):665-70. PubMed ID: 26780098
[TBL] [Abstract][Full Text] [Related]
3. Effect of prophylactic intraocular pressure-lowering medication (brinzolamide) on intraocular pressure after ranibizumab intravitreal injection: A case-control study.
Song S; Yu XB; Dai H
Indian J Ophthalmol; 2016 Oct; 64(10):762-766. PubMed ID: 27905340
[TBL] [Abstract][Full Text] [Related]
4. Sustained intraocular pressure elevation in eyes treated with intravitreal injections of anti-vascular endothelial growth factor for diabetic macular edema in a real-life setting.
Vo Kim S; Fajnkuchen F; Sarda V; Qu-Knafo L; Bodaghi B; Giocanti-Aurégan A
Graefes Arch Clin Exp Ophthalmol; 2017 Nov; 255(11):2165-2171. PubMed ID: 28831613
[TBL] [Abstract][Full Text] [Related]
5. Effect of prior glaucoma surgery on intraocular pressure immediately after anti-vascular endothelial growth factor injection.
Lam J; Luttrell I; Ding L; Rezaei K; Chao JR; Chee Y; Olmos De Koo LC; Wen JC
Graefes Arch Clin Exp Ophthalmol; 2019 Nov; 257(11):2489-2494. PubMed ID: 31388743
[TBL] [Abstract][Full Text] [Related]
6. Short-term effects and safety of an acute increase of intraocular pressure after intravitreal bevacizumab injection on corneal endothelial cells.
Park J; Lee M
BMC Ophthalmol; 2018 Jan; 18(1):17. PubMed ID: 29368595
[TBL] [Abstract][Full Text] [Related]
7. Monitoring intraocular pressure changes after intravitreal Ranibizumab injection using rebound tonometry.
Fuest M; Kotliar K; Walter P; Plange N
Ophthalmic Physiol Opt; 2014 Jul; 34(4):438-44. PubMed ID: 24731161
[TBL] [Abstract][Full Text] [Related]
8. Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections.
Frenkel MP; Haji SA; Frenkel RE
Arch Ophthalmol; 2010 Dec; 128(12):1523-7. PubMed ID: 21149773
[TBL] [Abstract][Full Text] [Related]
9. EFFECT OF SERIAL ANTERIOR CHAMBER PARACENTESIS ON SUSTAINED INTRAOCULAR PRESSURE ELEVATION IN PATIENTS RECEIVING INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
Sisk RA; Rusia D; Zamora BG; Kuley A; Toussaint BW
Retina; 2019 Oct; 39(10):1959-1964. PubMed ID: 30234855
[TBL] [Abstract][Full Text] [Related]
10. Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib.
Choi DY; Ortube MC; McCannel CA; Sarraf D; Hubschman JP; McCannel TA; Gorin MB
Retina; 2011 Jun; 31(6):1028-35. PubMed ID: 21836409
[TBL] [Abstract][Full Text] [Related]
11. Intraocular Pressure Changes in Non-Glaucomatous Patients Receiving Intravitreal Anti-Vascular Endothelial Growth Factor Agents.
Kiddee W; Montriwet M
PLoS One; 2015; 10(9):e0137833. PubMed ID: 26360382
[TBL] [Abstract][Full Text] [Related]
12. Clinical predictors of sustained intraocular pressure elevation due to intravitreal anti-vascular endothelial growth factor therapy.
Hoang QV; Tsuang AJ; Gelman R; Mendonca LS; Della Torre KE; Jung JJ; Freund KB
Retina; 2013 Jan; 33(1):179-87. PubMed ID: 22990314
[TBL] [Abstract][Full Text] [Related]
13. ASSOCIATION BETWEEN NEEDLE SIZE, POSTINJECTION REFLUX, AND INTRAOCULAR PRESSURE SPIKES AFTER INTRAVITREAL INJECTIONS.
Pang CE; Mrejen S; Hoang QV; Sorenson JA; Freund KB
Retina; 2015 Jul; 35(7):1401-6. PubMed ID: 25650712
[TBL] [Abstract][Full Text] [Related]
14. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents.
Kim JE; Mantravadi AV; Hur EY; Covert DJ
Am J Ophthalmol; 2008 Dec; 146(6):930-4.e1. PubMed ID: 18775528
[TBL] [Abstract][Full Text] [Related]
15. Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections.
Adelman RA; Zheng Q; Mayer HR
J Ocul Pharmacol Ther; 2010 Feb; 26(1):105-10. PubMed ID: 20187807
[TBL] [Abstract][Full Text] [Related]
16. Hypotensive efficacy of topical brimonidine for intraocular pressure spikes following intravitreal injections of antivascular endothelial growth factor agents: a randomised crossover trial.
Felfeli T; Hostovsky A; Trussart R; Yan P; Brent MH; Mandelcorn ED
Br J Ophthalmol; 2019 Oct; 103(10):1388-1394. PubMed ID: 30573499
[TBL] [Abstract][Full Text] [Related]
17. Intraocular pressure changes related to intravitreal injections of ranibizumab: analysis of pseudophakia and glaucoma subgroup.
Demirel S; Yanik O; Batioglu F; Ozmert E
Int Ophthalmol; 2015 Aug; 35(4):541-7. PubMed ID: 25079762
[TBL] [Abstract][Full Text] [Related]
18. A prospective study of blood pressure and intraocular pressure changes in hypertensive and nonhypertensive patients after intravitreal bevacizumab injection.
Lee K; Yang H; Lim H; Lew HM
Retina; 2009; 29(10):1409-17. PubMed ID: 19816242
[TBL] [Abstract][Full Text] [Related]
19. Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections.
Hoang QV; Mendonca LS; Della Torre KE; Jung JJ; Tsuang AJ; Freund KB
Ophthalmology; 2012 Feb; 119(2):321-6. PubMed ID: 22054994
[TBL] [Abstract][Full Text] [Related]
20. Persistent elevation of intraocular pressure following intravitreal injection of bevacizumab.
Segal O; Ferencz JR; Cohen P; Nemet AY; Nesher R
Isr Med Assoc J; 2013 Jul; 15(7):352-5. PubMed ID: 23943979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
